Expert: VH-only domain antibody (VHH) targeting CD40L. Inhibits CD40L-CD40 interaction, blocking T-cell co-stimulation, B-cell activation, and inflammatory cytokine production.
Everyday: Blocks the CD40L signal that tells immune cells to ramp up the attack. In autoimmune diseases like Sjogren's, the immune system wrongly attacks moisture-producing glands — this drug tells it to stand down.
Targets: ["CD40L"]
First-in-class CD40L inhibitor. Two Phase 3 studies in Sjogren's syndrome BOTH fully enrolled, data expected 2026. Addresses major unmet need — no approved therapy for Sjogren's. Also positive Phase 2 in discoid lupus (daxdilimab).